Literature DB >> 33709106

β-blocker use and risk of all-cause mortality in patients with coronary heart disease: effect modification by serum vitamin A.

Indu Dhar1, Gard F T Svingen2, Thomas Olsen3, Vegard Lysne1,2, Espen Ø Bjørnestad4, Per M Ueland5, Ottar K Nygård1,2.   

Abstract

AIMS: Blockade of β-adrenoceptors reduces sympathetic nervous system activity and improves survival in patients with heart failure with reduced left ventricular ejection fraction (HFrEF); however, any improvement in longevity among patients with coronary heart disease (CHD) but without HFrEF remains uncertain. Vitamin A has been linked to the activation of tyrosine hydroxylase, the rate-limiting enzyme in the catecholamine synthesis pathway. We investigated if vitamin A status modified the association of β-blocker use with the risk of all-cause mortality. METHODS AND
RESULTS: A total of 4118 patients undergoing elective coronary angiography for suspected stable angina pectoris, of whom the majority had normal left ventricular ejection fraction (LVEF) were studied. Hazard ratios (HRs) of all-cause mortality comparing treatment vs. non-treatment of β-blockers according to the tertiles of serum vitamin A were explored in Cox proportional hazards regression models. During a median follow-up of 10.3 years, 897 patients (21.8%) died. The overall LVEF was 65% and 283 (6.9%) had anamnestic HF. After multivariable adjustments for traditional risk factors, medical history, and drug therapies of cardiovascular disease, β-blocker treatment was inversely associated with the risk of all-cause mortality [HR : 0.84; 95% CI (confidence interval), 0.72-0.97]. However, the inverse association was generally stronger among patients in the upper serum vitamin A tertile (HR :0.66; 95% CI, 0.50-0.86; Pinteraction = 0.012), which remained present after excluding patients with LVEF < 40%.
CONCLUSION: In patients with suspected CHD, β-blocker treatment was associated with improved survival primarily among patients with high serum vitamin A levels.
© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.

Entities:  

Keywords:  Coronary heart disease; Epidemiology; Mortality; β-blocker therapy

Mesh:

Substances:

Year:  2022        PMID: 33709106     DOI: 10.1093/eurjpc/zwaa158

Source DB:  PubMed          Journal:  Eur J Prev Cardiol        ISSN: 2047-4873            Impact factor:   7.804


  1 in total

1.  Retinol and Retinol Binding Protein 4 Levels and Cardiometabolic Disease Risk.

Authors:  Matthias B Schulze; Clemens Wittenbecher; Catarina Schiborn; Daniela Weber; Tilman Grune; Ronald Biemann; Susanne Jäger; Natascha Neu; Marie Müller von Blumencron; Andreas Fritsche; Cornelia Weikert
Journal:  Circ Res       Date:  2022-08-26       Impact factor: 23.213

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.